Multicenter Evaluation of [−2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer | Zendy

Carsten Stephan | Zendy; S. Vincendeau | Zendy; A. Houlgatte | Zendy; Henning Cammann | Zendy; Klaus Jung | Zendy; Axel Semjonow | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multicenter Evaluation of [−2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer

Author(s) -

Carsten Stephan,

S. Vincendeau,

A. Houlgatte,

Henning Cammann,

Klaus Jung,

Axel Semjonow

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2012.195784

Subject(s) - prostate specific antigen , prostate cancer , medicine , prostate , multicenter study , index (typography) , oncology , antigen , cancer , urology , immunology , computer science , world wide web , randomized controlled trial

Total prostate-specific antigen (tPSA) is flawed for prostate cancer (PCa) detection. [-2]proprostate-specific antigen (p2PSA), a molecular isoform of free PSA (fPSA), shows higher specificity compared with tPSA or percentage of free PSA (%fPSA). The prostate health index (Phi), a measure based on p2PSA and calculated as p2PSA/fPSA × √tPSA, was evaluated in a multicenter study for detecting PCa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research